Protagenic Therapeutics, Inc.
PTIXW
NASDAQ Capital Market0.02
USD
+0.00
- -
CIK
0001022899
ISIN
US74365N1110
CUSIP
74365N111
Return %
Stock
S&P500
1Y
233.33
26.53
3Y
-63.59
76.60
5Y
-95.45
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Garo H. Armen
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 149 Fifth Avenue New York City NY United States of America 10010
- IPO Date
- Apr 27, 2021
- CIK
- 0001022899
- Website
- protagenic.com
- Similar Companies
- Business
- Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc. is a New York-based biopharmaceutical company focused on the discovery and development of novel therapeutics targeting stress-related neuropsychiatric and central nervous system (CNS) disorders, including PTSD, depression, anxiety, substance abuse, obesity, and metabolic conditions. Founded in 2004 and headquartered at 149 Fifth Avenue, Suite 500, New York, New York, the company advances a pipeline of approximately six drug candidates, comprising its lead asset PT-00114, a synthetic teneurin C-terminal associated peptide (TCAP) in Phase I/IIa clinical development pursuing a biologics license application pathway with potential regulatory data exclusivity; PHYX-001, a preclinical potassium channel modulator with mechanisms akin to XEN1101 and BHV-7000; multiple cannabinoid-based compounds protected by composition-of-matter intellectual property for CNS, cardiometabolic, and obesity indications including metabolic dysfunction-associated steatotic liver disease; and modified stilbenoid compounds exhibiting preclinical anticonvulsant activity. The company operates primarily in the United States with a global focus on unmet needs in neuropsychiatry and neurodegeneration driven by stress feedback loops. In May 2025, Protagenic Therapeutics completed a transformative all-stock business combination with Phytanix Bio Inc., creating a combined entity with expanded preclinical assets, enhanced CNS expertise from teams experienced in Sativex and Epidiolex at GW Pharmaceuticals, broader patent protection, and diversified pipeline milestones anticipated over the next 18 months; the transaction involved issuing shares, preferred stock, and warrants to Phytanix stockholders, resulting in approximately 35% post-combination ownership for pre-combination Protagenic shareholders on a fully diluted basis, while retaining the Protagenic Therapeutics name and Nasdaq listing under PTIX. In November 2025, the company received a Nasdaq non-compliance notice related to merger financial consolidation delays.